

Operational Progress Delivered a Stable 1H FY26 result

Genetic Signatures [ASX:GSS] (“GSS” or “the Company”), a global molecular diagnostics company is pleased to announce the results for the half year ended 31 December 2025 (1H FY26).

HIGHLIGHTS

- Statutory revenue of \$8.7 million for the half year broadly consistent with pcp (\$8.5 million, 1H FY25). Revenue was driven primarily by respiratory testing demand in Australia during the winter season, together with contributions from the EMEA region and the United States
- Gross Profit of \$4.8 million (GP margin, 55.7%) compared to \$5.0 million pcp (1H FY25, GP margin 58.8%) declined for the period by \$0.2 million driven by increased costs of consumables and raw materials for respiratory test kits
- An improvement in the reported net loss to \$6.4 million for the half year (\$8.4 million 1H FY25, or \$15.2 million including non-recurring impairment expenses)
- Customer growth in US market continues with a second contracted customer commencing in the period, with a third progressing through implementation and expected to commence testing this quarter
- In the UK, the team continued to work with multiple NHS trusts, where Genetic Signatures’ GI viral, bacterial, and parasite test kits are being used in hospital settings to support infection control and outbreak prevention
- Maria Halasz appointed CEO effective from 2 March 2026, in conjunction with the appointment of Anne Lockwood as Interim Managing Director for a six-month period
- As at 31 December 2025, Genetic Signatures held \$29.9 million in cash and cash equivalents, including term deposits classified as other financial assets and \$44.1 million of net assets

Financial Results

For the half ending 31 December 2025, Genetic Signatures reported revenue of \$8.7 million for the half year (\$8.5 million 1H FY25). Revenue continued to be driven primarily by respiratory testing demand in Australia during the winter season, together with contributions from the EMEA region and the United States.

Gross margin of \$4.8 million (GP margin, 55.7%) compared to \$5.0 million (1H FY25, GP margin 58.8%) declined for the period by \$0.2 million driven by increased costs of consumables and raw materials for respiratory test kits.

A focus on cost discipline, resulted in a reduction in operating expenses of \$0.6 million for the half. An increase in other income of \$1.6 million, largely from the Research and Development Tax Incentive program

drove a reduction in operating losses, with the Group reporting a net loss of \$6.4 million for the half year (\$8.4 million 1H FY25 \$15.2 million including non-recurring impairment expenses).

As at 31 December 2025, Genetic Signatures remains in a strong cash position with \$29.9 million in cash and cash equivalents including term deposits classified as other financial assets, a decline of \$1.4 million from \$31.3 million at 30 June 2025. During the half year, the Company received \$4.4 million under the Research and Development Tax Incentive program for eligible expenditures incurred in the financial year ended 30 June 2025 and used \$5.2 million in operating activities and \$0.6 million on plant and equipment.

Supporting initial US customer sites to increase throughput

The Company continued to work closely with its three contracted customers to implement the EasyScreen™ Gastrointestinal Parasite Detection Kit, providing hands-on commercial and technical support to ensure smooth onboarding and integration into routine testing workflows.

During Q2 FY26, a second contracted customer went live, with products delivered to site for go-live. The third customer has progressed through implementation activities and operational readiness, with testing expected to commence during the current quarter.

The sales team remains engaged with all contracted customers to support any increase in testing volumes, focusing on optimising workflows, expanding use cases, and embedding EasyScreen™ into standard diagnostic protocols. These initial deployments are now functioning as reference sites, demonstrating clinical and operational value and supporting further customer engagement and conversion to sales.

Team engaged in EMEA to support evaluations of GI portfolio

The team continued to work with multiple NHS trusts in the UK, where Genetic Signatures' GI viral, bacterial, and parasite test kits are being used in hospital settings to support infection control and outbreak prevention. To date, these engagements have generated supportive clinical data, reinforcing the value of our proposition to a growing number of potential clients. The team continued to pursue further evaluations to facilitate future growth in this region. Genetic Signatures continues to work with external distribution partners across the EMEA region.

Progress on new instruments and software and R&D

Development progressed on the Company's new instrument and software platform, in collaboration with Tecan Group and Repado. Phase II will focus on integrated hardware and software customisation, enabling workflow optimisation, laboratory analytics and enhanced service capability.

A comprehensive market assessment, incorporating feedback from more than 200 industry professionals, is shaping the expanded 3base® syndromic testing menu to be launched alongside the new platform.

Leadership change at Genetic Signatures

On 2 February 2026 the Company announced the appointment of Maria Halasz as CEO effective 2 March 2026, following the departure of Allison Rossiter. Ms Halasz has substantial experience leading commercialising in the life sciences sector including diagnostics, having served for 14 years as Chief Executive Officer and Managing Director of Anagenics Limited (formerly Cellmid Limited, ASX: AN1).

On 6 February 2026 the Company further announced the appointment of Non-Executive Director Anne Lockwood as interim Managing Director for a period of up to six months to ensure continuity of the business during a significant leadership transition. Given Anne's in-depth experience as a CFO, the appointment of a

permanent CFO will be deferred during this period.

During the half year, Dr Susanne Pedersen was appointed Chief Technology Officer. Dr Pedersen holds a PhD in molecular biology and has more than 25 years' experience in the development and commercialisation of molecular in vitro diagnostic products.

Outlook

The Company remains focused on strengthening its presence in Australia while accelerating global expansion. The Board remains confident in the Company's strategy to continue diversifying revenue by growing international markets beyond its current primarily domestic business.

The Board continues to review the operational and financial performance of the business, including detailed analyses of its operating costs. This review aims to streamline the business whilst continuing to build its operating business, particularly the US market which is demonstrating customer uptake.

In addition the Board has commenced a review of the business aimed at maximising shareholder value. The Company has appointed advisors to support this process. The Company will keep shareholders informed in accordance with its continuous disclosure obligations.

Caroline Waldron, Chair of Genetic Signatures said *"Our first half performance reflects the steady progress we are making in executing our global commercial strategy. Stable respiratory testing demand in Australia, together with early traction across the US and EMEA regions, have contributed to revenue stability and an improved operating performance."*

We are pleased to have been able to convert former US evaluation sites into contracted customers. The Company's development programs, including our new instrument and software platform, continue to focus on meeting evolving customer needs."

The Board would like to thank shareholders for their ongoing patience as we move through the transition of leadership.

– END –

Announcement authorised by Genetic Signatures' Board of Directors

For further information, see our website (www.geneticsignatures.com) or contact us:

Daniel Ireland

Investor Relations

daniel.ireland@datair.com.au

0428 607 884

About Genetic Signatures Limited: Genetic Signatures is a specialist molecular diagnostics company, specialising in detecting infectious diseases, using patented 3base® technology to simplify the genetic complexity of pathogen identification. Automated diagnostic workflows accurately screen for multiple infectious pathogens with similar symptoms, in a single test. Genetic Signatures' unique solutions enable laboratories to enhance diagnostic workflow and efficiencies, while reducing costs. Rapid results support infection control, appropriate patient management and disease surveillance, improving healthcare outcomes. Genetic Signatures continues to expand its global presence with direct representation in Australia, the United States and Europe, alongside international distribution partnerships.